68 results
8-K
EX-10.4
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
on such relative value, such disagreement shall be referred to an independent expert in accordance with the provisions of Exhibit A.
Exhibit 10.4 … of Expert
If any party wishes to appoint an independent expert (the "Expert") to determine any matter pursuant to Section 1.30 (or if the parties
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Aug 08
Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors
12:00am
of the Board and as the Company’s audit committee financial expert. Todd C. Davis, a current director and member of the Audit Committee, has been appointed … as interim chairperson of the Audit Committee and designated the new audit committee financial expert.
(d) Based upon the recommendation of the Board’s
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 May 18
Ligand Reports First Quarter 2018 Financial Results
4:08pm
potentially for EVOMELA, which has a regulatory application outstanding under priority review with an Expert Advisory Committee review date of April 25
8-K
EX-99.1
xincj9yo4ugs7ihgotp6
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-99.1
5sop1z609m2
4 Dec 12
Regulation FD Disclosure
12:00am
8-K
EX-99.1
2oeqdc2vekka6 qc2t7
18 Nov 14
Regulation FD Disclosure
12:00am
8-K
EX-99
zjpt6 u4yqcs8g
11 Sep 06
Regulation FD Disclosure
12:00am
424B3
24rylnovmwrcwzg
15 May 06
Prospectus supplement
12:00am